Table 3.

Cox regression analyses. Hazard ratios for risk of ustekinumab discontinuation.

Univariate Analyses	p	HR (95% CI)
Psoriasis onset ≥ 40 years	0.514	0.785 (0.386–1.597)
Sex (male)	0.456	0.789 (0.423–1.471)
Obesity: BMI ≥ 30	0.115	0.614 (0.335–1.127)
Arthritis: yes	<0.001	3.623 (1.876–6.993)
Diabetes: yes	0.301	0.702 (0.359–1.372)
Hypertension arterial: yes	0.580	0.839 (0.450–1.564)
Dyslipidemia: yes	0.263	1.443 (0.759–2.741)
Family history: yes	0.181	0.624 (0.313–1.244)
Naive patients:	0.03	0.476 (0.243–0.932)
Multivariate analysis	p	95% CI
Arthritis: yes	0.001	3.344 (1.639–6.849)
Naive patients	0.286	0.683 (0.339–1.736)